Safety and efficacy of long-acting injectable risperidone in daily practice: An open-label, noninterventional, prospective study in schizophrenia and related disorders

International Clinical Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 149-154

  Parellada, Eduard ^a   Kouniakis, Filippos ^b   Siurkute, Aldona ^c   Schreiner, Andreas ^d   Don, Liana ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Republican Vilnius Psychiatric Hospital   (Spain)

^d Medical Affairs EMEA ^*  (United Kingdom)

^e IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Antipsychotic; Injectable; Long acting; Risperidone; Schizophrenia

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; CLOZAPINE; CYAMEMAZINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LORAZEPAM; LOXAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIOTIAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; ZIPRASIDONE; ZOLPIDEM; ZOPICLONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ABNORMAL BEHAVIOR; ADOLESCENT; ADULT; AGED; AGGRESSION; AGITATION; AKATHISIA; ALCOHOLISM; AMENORRHEA; ANXIETY; ARTICLE; BODY WEIGHT; CATATONIC SCHIZOPHRENIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; DELUSION; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; GALACTORRHEA; HALLUCINATION; HEBEPHRENIA; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; OPEN STUDY; PARANOID SCHIZOPHRENIA; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RESIDUAL SCHIZOPHRENIA; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA;

EID: 77950944922     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328336c93f     Document Type: Article

References (22)

1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
2. Arango C, Gómez-Beneyto M, Brenlla J, Gastó C, Sarramea-Crespo F, Chamorro L, et al. (2007). A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Eur Neuropsychopharmacol 17:456-463.
3. Correll CU, Schenk EM (2008). Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:151-156.
4. De Jong Z, Munneke M, Jansen LM, Ronday K, van Schaardenburg DJ, Brand R, et al. (2004). Differences between participants and nonparticipants in an exercise trial for adults with rheumatoid arthritis. Arthritis Rheum 51:593-600.
5. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, et al. (2006). Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 106:2452-2458.
6. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257.
7. Gasquet I, Haro JM, Novick D, Edgell DT, Kennedy L, Lepine JP, SOHO Study Group (2005). Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 20:199-205.
8. Goss CH, Rubenfeld GD, Ramsey BW, Aitken ML (2006). Clinical trial participants compared with nonparticipants in cystic fibrosis. Am J Respir Crit Care Med 173:98-104.
9. Guy W (1976). Clinical global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Vol.76. Rockville, MD: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch. pp. 218-222.
10. Kane JM (2006). Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 67 (Suppl 5):9-14.
11. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
12. Leucht S, Heres S (2006). Epidemiology, clinical consequences, and psycho-social treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 (Suppl 5):3-8.
13. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M (2004). Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65:1084-1089.
14. Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E (2005). Efficacy and safety of direct transition to risperidone long-acting inject-able in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20:121-130.
15. Moore TA, Covell NH, Essock SM, Miller AL (2007). Real-world antipsychotic treatment practices. Psychiatr Clin North Am 30:401-416.
16. Pajonk F, Schreiner A, Peters S, Rettig K, Degner D, Ruther E (2005). Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. J Clin Psychopharmacol 25:293-300.
17. Pappadoppulos E, Jensen PS, Schur SB, MacIntyre JC II, Ketner S, Van Orden K, et al. (2002). Real world atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 28:111-121.
18. Parellada E (2006). Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin 22:241-255.
19. Riedel M, Strassing M, Müller N, Zwack P, Möller HJ (2005). How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255:143-148.
20. Sesso HD, Gaziano JM, VanDenburgh M, Hennekens CH, Glynn RJ, Buring JE (2002). Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study. Control Clin Trials 23:686-702.
21. Velicer WF, Keller S, Friedman RH, Fava JL, Gulliver SB, Ward RM, et al. (2005). Comparing participants and nonparticipants recruited for an effectiveness study of nicotine replacement therapy. Ann Behav Med 29:181-191.
22. Woods SW, Ziedonis DM, Sernyak MJ, Diaz E, Rosenheck RA (2000). Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr Serv 51:79-84.